Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Vaccines for Zoonotic, High-Consequence Pathogens: A One Health Approach to...
share announcement

Vaccines for Zoonotic, High-Consequence Pathogens: A One Health Approach to Disease Control

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Infectious Diseases".

Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 17012

Special Issue Editors

Dr. Richard Bennett

E-Mail Website
Guest Editor
Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA
Interests: zoonotic diseases
Dr. Jessica Spengler

E-Mail Website
Guest Editor
National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, USA
Interests: innate Immunity; pathogenesis; bunyavirus
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Our growing population has resulted in increased wildlife interactions through habitat encroachment by agriculture, mining, and housing development. In addition, continued hunting of wild animals as food sources and an increased demand for exotic pets have facilitated opportunities for pathogens to infect new species, including humans. Global movement of humans and goods has allowed the spread of novel viruses around the world at an increasingly rapid pace, making disease control efforts exceptionally challenging. The introductions of influenza (of swine or avian origin), Nipah virus, Hendra virus, Ebola virus, and novel corona viruses (SARS, MERS, and now SARS-2) into the human population highlight the need for disease control measures directed at both human and animal hosts.

This Special Issue will focus on the One Health approach to vaccine development to control infectious disease in both animal and human populations. All types of articles will be considered for publication, including short reports, primary research articles, and reviews.

Dr. Richard Bennett
Dr. Jessica Spengler
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccines
  • zoonotic disease
  • high-consequence pathogens
  • disease control
  • human and animal
  • wildlife
  • global health

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

13 pages, 17561 KiB  
Article
Sero-Monitoring of Horses Demonstrates the Equivac® HeV Hendra Virus Vaccine to Be Highly Effective in Inducing Neutralising Antibody Titres
by Kim Halpin, Kerryne Graham and Peter A. Durr
Vaccines 2021, 9(7), 731; https://doi.org/10.3390/vaccines9070731 - 02 Jul 2021
Cited by 6 | Viewed by 3255
Abstract
Hendra virus (HeV) is a high consequence zoonotic pathogen found in Australia. The HeV vaccine was developed for use in horses and provides a One Health solution to the prevention of human disease. By protecting horses from infection, the vaccine indirectly protects humans [...] Read more.
Hendra virus (HeV) is a high consequence zoonotic pathogen found in Australia. The HeV vaccine was developed for use in horses and provides a One Health solution to the prevention of human disease. By protecting horses from infection, the vaccine indirectly protects humans as well, as horses are the only known source of infection for humans. The sub-unit-based vaccine, containing recombinant HeV soluble G (sG) glycoprotein, was released by Pfizer Animal Health (now Zoetis) for use in Australia at the end of 2012. The purpose of this study was to collate post-vaccination serum neutralising antibody titres as a way of assessing how the vaccine has been performing in the field. Serum neutralization tests (SNTs) were performed on serum samples from vaccinated horses submitted to the laboratory by veterinarians. The SNT results have been analysed, together with age, dates of vaccinations, date of sampling and location. Results from 332 horses formed the data set. Provided horses received at least three vaccinations (consisting of two doses 3–6 weeks apart, and a third dose six months later), horses had high neutralising titres (median titre for three or more vaccinations was 2048), and none tested negative. Full article
(This article belongs to the Special Issue Vaccines for Zoonotic, High-Consequence Pathogens: A One Health Approach to Disease Control)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

12 pages, 1816 KiB  
Review
Better Pandemic Influenza Preparedness through Adjuvant Technology Transfer: Challenges and Lessons Learned
by Céline H. Lemoine, Reviany V. Nidom, Roland Ventura, Setyarina Indrasari, Irine Normalina, Kuncoro Puguh Santoso, Francis Derouet, Christophe Barnier-Quer, Gerrit Borchard, Nicolas Collin and Chairul A. Nidom
Vaccines 2021, 9(5), 461; https://doi.org/10.3390/vaccines9050461 - 05 May 2021
Cited by 9 | Viewed by 3200
Abstract
Adequate global vaccine coverage during an influenza pandemic is essential to mitigate morbidity, mortality, and economic impact. Vaccine development and production needs to be sufficient to meet a vast global demand, requiring international cooperation and local vaccine production capacity, especially in resource-constrained countries. [...] Read more.
Adequate global vaccine coverage during an influenza pandemic is essential to mitigate morbidity, mortality, and economic impact. Vaccine development and production needs to be sufficient to meet a vast global demand, requiring international cooperation and local vaccine production capacity, especially in resource-constrained countries. The use of adjuvants is one approach to augment the number of available vaccine doses and to overcome potential vaccine shortages. Appropriately selected adjuvant technologies can decrease the amount of vaccine antigen required per dose, may broaden or lengthen the conferred protection against disease, and may even allow protective single-dose vaccination. Here we describe a technology transfer collaboration between Switzerland and Indonesia that led to the establishment of a vaccine formulation platform in Surabaya which involved the transfer of equipment and expertise to enable research and development of adjuvanted vaccine formulations and delivery systems. This new Indonesian capability aims to facilitate local and regional access to know-how relating to adjuvanted vaccine formulations, thus promoting their application to local vaccine developers. In this review, we aim to share the “lessons learned” from this project to both support and inspire future scientific collaborations of a similar nature. Full article
(This article belongs to the Special Issue Vaccines for Zoonotic, High-Consequence Pathogens: A One Health Approach to Disease Control)
►▼ Show Figures

Figure 1

31 pages, 789 KiB  
Review
Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats
by Sophia M. Vrba, Natalie M. Kirk, Morgan E. Brisse, Yuying Liang and Hinh Ly
Vaccines 2020, 8(4), 680; https://doi.org/10.3390/vaccines8040680 - 13 Nov 2020
Cited by 48 | Viewed by 7076
Abstract
Vaccination is arguably the most cost-effective preventative measure against infectious diseases. While vaccines have been successfully developed against certain viruses (e.g., yellow fever virus, polio virus, and human papilloma virus HPV), those against a number of other important public health threats, such as [...] Read more.
Vaccination is arguably the most cost-effective preventative measure against infectious diseases. While vaccines have been successfully developed against certain viruses (e.g., yellow fever virus, polio virus, and human papilloma virus HPV), those against a number of other important public health threats, such as HIV-1, hepatitis C, and respiratory syncytial virus (RSV), have so far had very limited success. The global pandemic of COVID-19, caused by the SARS-CoV-2 virus, highlights the urgency of vaccine development against this and other constant threats of zoonotic infection. While some traditional methods of producing vaccines have proven to be successful, new concepts have emerged in recent years to produce more cost-effective and less time-consuming vaccines that rely on viral vectors to deliver the desired immunogens. This review discusses the advantages and disadvantages of different viral vaccine vectors and their general strategies and applications in both human and veterinary medicines. A careful review of these issues is necessary as they can provide important insights into how some of these viral vaccine vectors can induce robust and long-lasting immune responses in order to provide protective efficacy against a variety of infectious disease threats to humans and animals, including those with zoonotic potential to cause global pandemics. Full article
(This article belongs to the Special Issue Vaccines for Zoonotic, High-Consequence Pathogens: A One Health Approach to Disease Control)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

9 pages, 239 KiB  
Commentary
Selection of Filovirus Isolates for Vaccine Development Programs
by Daniel N. Wolfe, Carol L. Sabourin, Michael J. Merchlinsky, William C. Florence, Larry A. Wolfraim, Kimberly L. Taylor and Lucy A. Ward
Vaccines 2021, 9(9), 1045; https://doi.org/10.3390/vaccines9091045 - 19 Sep 2021
Cited by 5 | Viewed by 2229
Abstract
The continuing outbreaks of ebola virus disease highlight the ongoing threat posed by filoviruses. Fortunately, licensed vaccines and therapeutics are now available for Zaire ebolavirus. However, effective medical countermeasures, such as vaccines for other filoviruses such as Sudan ebolavirus and the Marburg [...] Read more.
The continuing outbreaks of ebola virus disease highlight the ongoing threat posed by filoviruses. Fortunately, licensed vaccines and therapeutics are now available for Zaire ebolavirus. However, effective medical countermeasures, such as vaccines for other filoviruses such as Sudan ebolavirus and the Marburg virus, are presently in early stages of development and, in the absence of a large outbreak, would require regulatory approval via the U.S. Food and Drug Administration (FDA) Animal Rule. The selection of an appropriate animal model and virus challenge isolates for nonclinical studies are critical aspects of the development program. Here, we have focused on the recommendation of challenge isolates for Sudan ebolavirus and Marburg virus. Based on analyses led by the Filovirus Animal and Nonclinical Group (FANG) and considerations for strain selection under the FDA Guidance for the Animal Rule, we propose prototype virus isolates for use in nonclinical challenge studies. Full article
(This article belongs to the Special Issue Vaccines for Zoonotic, High-Consequence Pathogens: A One Health Approach to Disease Control)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop